Cempra Inc (CEMP)

2.95
NASDAQ : Health Care
Prev Close 3.00
Day Low/High 2.85 / 3.00
52 Wk Low/High 2.55 / 26.95
Avg Volume 765.10K
Exchange NASDAQ
Shares Outstanding 52.51M
Market Cap 157.53M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Malin Investee Company - Melinta Therapeutics - To Be Transformed Into A NASDAQ Listed Company

Malin Investee Company - Melinta Therapeutics - To Be Transformed Into A NASDAQ Listed Company

Malin Corporation plc. (ISE:MLC, "Malin"), an Irish based and globally operating life sciences company, today announced that Melinta Therapeutics, Inc.

Cempra Provides Corporate Update And Reports Second Quarter 2017 Financial Results

Cempra Provides Corporate Update And Reports Second Quarter 2017 Financial Results

Management to host webcast and conference call today at 8:45 a.m. ET

Cempra To Report Second Quarter 2017 Financial Results

Cempra To Report Second Quarter 2017 Financial Results

Management to host webcast and conference call on Wednesday, August 9, 2017 at 8:45 a.m. ET

Short Interest Decreases By 10.7% For CEMP

Short Interest Decreases By 10.7% For CEMP

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 581,412 share decrease in total short interest for Cempra Inc , to 4,850,555, a decrease of 10.70% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cempra Reports First Quarter 2017 Financial Results And Provides Corporate Update

Management to host webcast and conference call today at 8:45 a.m. ET

Cempra To Report First Quarter 2017 Financial Results

—Management to host webcast and conference call on Friday, April 28, 2017 at 8:45 a.m. ET—

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Tesaro, Editas

Cempra, Tesaro and Editas Medicine were among the biotech stock movers in premarket trading on Tuesday.

Cempra Withdraws Solithromycin Marketing Authorization Application In Europe

—Company plans to resubmit MAA with additional data, in alignment with FDA strategy—

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Cempra, Blueprint Medicines and  Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Monday.

Cempra To Present At 29th Annual ROTH Conference

—Presentation time at Cowen and Company 37th Annual Health Care Conference on Monday, March 6 changed to 2:40 p.m. ET—

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: Cempra, Novavax, Ionis

Cempra, Novavax and Ionis Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Biotech Movers: Cempra Flys High On Phase Three Results

Biotech Movers: Cempra Flys High On Phase Three Results

Other movers include Incyte, Achillion and Inovio.

Cempra To Report Fourth Quarter And Full Year 2016 Financial Results

Management to host webcast and conference call on Tuesday, February 28, 2017 at 8:45 a.m. EST

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.